P/Q-type (Cav2.1) anti-VGCC-ab are present in 85–90% of patients with LEMS, and nearly 100% of paraneoplastic LEMS, associated with SCLC (53, 54). Here, CACNA1A is linked to Lambert-Eaton myasthenic syndrome.